Yoda Therapeutics, a Taiwan-based biopharmaceutical company partnered with Alar Pharmaceuticals, is advancing its novel drug YA-101, designed for the treatment of Multiple System Atrophy (MSA). Following its successful Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA) on September 24, the company announced on December 5 that it has also received IND approval from Taiwan's Food and Drug Administration (TFDA).

A Strategic Partnership for Innovative Drug Development

In September 2023, Alar Pharmaceuticals and Yoda Therapeutics entered into a collaborative agreement to co-develop YA-101. Under the partnership, Alar is responsible for the development of the drug’s Chemistry, Manufacturing, and Controls (CMC), conducting pharmacokinetic studies, and providing technical documentation and consultation related to CMC. Meanwhile, Yoda Therapeutics oversees patent applications, clinical research, and commercialization efforts. The agreement stipulates that both parties will share profits from the drug's international licensing or eventual commercialization.

YA-101: A Taiwan-Developed First-in-Class Therapy

YA-101 is an innovative drug developed in Taiwan, designed using advanced AI-based models. It features dual functions: regulating the NLRP3 inflammasome and NMDA receptors, enabling it to both suppress inflammatory responses and restore neural activity. In 2022, the drug received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of MSA. Preclinical studies demonstrated significant therapeutic potential and safety, while Phase I clinical trials in Australia confirmed its good tolerability.

Targeting a Rare and Rapidly Progressive Disease

MSA is a rare, rapidly progressive neurodegenerative disorder that affects the autonomic nervous system and impairs motor functions. The global prevalence of MSA is estimated at 5 per 100,000 people, with onset typically occurring around the age of 50. Most patients become disabled within five years, and life expectancy after diagnosis ranges from 8 to 10 years. Currently, there is no effective treatment to slow disease progression or cure the condition.

YA-101 is poised to become a first-in-class therapy, offering new hope to MSA patients worldwide by providing an innovative and potentially effective treatment option.

Resource: 昱展結盟思捷優達之新藥YA-101，台、美國同獲准進二期臨床試驗